Amgen and Allergan plc. announced positive top-line results from Avastin biosimilar candidate ABP 215, which met its primary and secondary endpoints in a phase III trial in advanced non-squamous non-small cell lung cancer.
FDA granted Priority Review for alectinib, an oral investigational anaplastic lymphoma kinase inhibitor, for the treatment of people with ALK-positive, locally advanced or metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.
Today, 836 medicines and vaccines are in development for cancer by U.S. biopharmaceutical companies—all of which are either in clinical trials or awaiting review by the FDA—according to a report from the Pharmaceutical Research and Manufacturers of America.
CHAD MIRKIN was named the inaugural recipient of the Raymond and Beverly Sackler Prize in Convergence Research by the National Academy of Sciences.
The Ontario Institute for Cancer Research and the Structural Genomics Consortium in Toronto developed a new drug prototype, called OICR-9429, and made it freely available to the research community.
Vaccinogen Inc. entered into an agreement with Dublin City University, through one of its subsidiaries, to provide an exclusive two-year option to evaluate and acquire a high-throughput, multiplex, analysis platform, DiCAST.
CVS Health marked the first anniversary of ending tobacco sales at its CVS/pharmacy locations, and released study data showing a reduction in cigarette purchases over the past year.
Sequenom Inc. entered into a clinical research collaboration with the University of California, San Diego Moores Cancer Center to explore the utility of Sequenom's new liquid biopsy assay to comprehensively profile circulating cell-free tumor DNA in blood to enable serial monitoring and assist with therapy selection in cancer patients.
Janssen Biotech Inc. announced an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in phase I clinical studies.
TROVAGENE INC. established the Trovagene Research Institute, a European subsidiary focused on expanding the capabilities and adoption of the company's Precision Cancer Monitoring platform. Trovagene has also entered into a collaboration with the Department of Oncology at the University of Torino.
